Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Moderate to Very Severe COPD
NCT06878261Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of tezepelumab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06878261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878261.